Omeros (OMER) Enterprise Value (2010 - 2026)
Omeros (OMER) posted Enterprise Value of -$135.3 million for Q1 2026, up 21.24% sequentially from -$171.8 million in Q4 2025, and down 158.18% YoY from $232.6 million in Q1 2025.
Omeros (OMER) Enterprise Value (2010 - 2026) Analysis & Trends
Omeros has reported Enterprise Value for 17 years, with the latest figure at -$135.3 million in Q1 2026.
- Quarterly Enterprise Value fell 158.18% year-over-year to -$135.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135.3 million (down 158.18% YoY) and the FY2025 annual result came in at -$171.8 million, down 90.61% from the prior year.
- Enterprise Value advanced to -$135.3 million in Q1 2026 per OMER's latest filing, from -$171.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$52.4 million in Q1 2025 and troughed at -$590.0 million in Q3 2023.
- A 5-year average of -$204.2 million and a median of -$158.9 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value tumbled 178.53% in 2023, then jumped 88.58% in 2025.
- Over 5 years, Enterprise Value stood at -$194.9 million in 2022, then rose by 11.84% to -$171.8 million in 2023, then jumped by 47.55% to -$90.1 million in 2024, then slumped by 90.61% to -$171.8 million in 2025, then advanced by 21.24% to -$135.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$135.3 million, -$171.8 million, and -$69.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | -131.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.95 Mn |
| Mar 31, 2026 | -135.32 Mn |
| Dec 31, 2025 | -171.80 Mn |
| Sep 30, 2025 | -69.79 Mn |
| Jun 30, 2025 | -55.54 Mn |
| Mar 31, 2025 | -52.41 Mn |
| Dec 31, 2024 | -90.13 Mn |
| Sep 30, 2024 | -123.16 Mn |
| Jun 30, 2024 | -158.91 Mn |
| Mar 31, 2024 | -458.80 Mn |
| Dec 31, 2023 | -171.85 Mn |
| Sep 30, 2023 | -589.97 Mn |
| Jun 30, 2023 | -341.28 Mn |
| Mar 31, 2023 | -371.33 Mn |
| Dec 31, 2022 | -194.92 Mn |
| Sep 30, 2022 | -220.96 Mn |
| Jun 30, 2022 | -122.53 Mn |
| Mar 31, 2022 | -142.27 Mn |
| Dec 31, 2021 | -157.26 Mn |
| Sep 30, 2021 | -93.36 Mn |